← back to search

Zicheng Zhang

Guangzhou University of Chinese Medicine · CN
Area of research
Nuclear and High Energy Physics · Cancer Research
Research interest
Research focused on Immune system and Immunotherapy, with related work in Colorectal cancer, Coronavirus disease 2019 (COVID-19), Transcriptome. Notable publications include 'Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer', 'The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response', and 'Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer'.
h-index
citations
670
works
10
NIH funding
primary concept
email

Recent publications

Obacunone Alleviates Thalamic Pain via Promoting LCN2-Mediated Phagocytosis of Astrocytes in Mice
ACS Chemical Neuroscience 2025cited by 3position: middledoi
Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess
Frontiers in Pharmacology 2024cited by 10position: middledoi
Improvement of the CGEM detector simulation with cosmic-rays
Journal of Instrumentation 2023cited by 0position: middledoi
Integrated immunogenomic analysis of single-cell and bulk tissue transcriptome profiling unravels a macrophage activation paradigm associated with immunologically and clinically distinct behaviors in ovarian cancer
Journal of Advanced Research 2022cited by 36position: middledoi
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response
npj Precision Oncology 2021cited by 117position: middledoi
Multiomics integration-based molecular characterizations of COVID-19
Briefings in Bioinformatics 2021cited by 48position: middledoi
Myopia progression and stabilization in school‐aged children with single‐vision lenses
Acta Ophthalmologica 2021cited by 31position: middledoi
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
Frontiers in Oncology 2021cited by 3position: middledoi
Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer
Journal for ImmunoTherapy of Cancer 2020cited by 312position: middledoi
Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer
Molecular Therapy — Nucleic Acids 2018cited by 110position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Meng Zhou · Chongqing Medical University5 papers (2018–2022)Jie Sun · Tianjin First Center Hospital5 papers (2018–2022)Nan Wu · Chongqing University2 papers (2018–2020)Congcong Yan · Wenzhou Medical University2 papers (2020–2022)Guangyu Wang · Tongji University2 papers (2021–2021)Dandan Xu · First Affiliated Hospital of Xinxiang Medical University2 papers (2021–2022)Fanling Meng · Harbin Medical University1 papers (2022–2022)Xiude Qin · Guangzhou University of Chinese Medicine1 papers (2025–2025) · 1 papers (2025–2025)Yu Zhao · Jiangnan University1 papers (2024–2024)Zhao-Hui Dang · Guangzhou University of Chinese Medicine1 papers (2025–2025)Xu Wang · Guangzhou University of Chinese Medicine1 papers (2025–2025)Siqi Bao · Harbin Medical University1 papers (2020–2020)Yue Ma · Harbin Medical University1 papers (2021–2021)Åsa M. Wheelock · Karolinska University Hospital1 papers (2021–2021)Qian Guo · Guiyang Medical University1 papers (2024–2024)Tongsen Zheng · Harbin Medical University1 papers (2021–2021)Song Gao · Guangzhou University of Chinese Medicine1 papers (2025–2025)Yunwei Lu · Guangzhou University of Chinese Medicine1 papers (2025–2025)Liangde Xu · Harbin Medical University1 papers (2020–2020)